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2. ABSTRACT 
 
Background and aims Colorectal cancer (CRC) is one of the world’s three 
most common cancers, and its incidence is rising. Novel biomarkers are 
essential for diagnostic and prognostic tools and to identify patients for targeted 
and individualized therapy. Covering all human cells, the carbohydrate units of 
glycoproteins, glycolipids, and proteoglycans are glycans. Carcinoma-related 
glycan structures are potential cancer biomarkers, since glycosylation evolves 
during carcinogenesis. Suggested to play a role in carcinogenesis are 
glycoproteins podocalyxin (PODXL) and regenerating islet-derived gene (REG) 
4. PODXL’s aberrant expression or allelic variation or both associate in 
different cancers with poor prognosis and unfavourable clinicopathological 
characteristics. Up-regulated REG4 expression occurs in inflammatory bowel 
diseases and also in gastrointestinal cancers. Reports on the association of 
REG4 expression with CRC prognosis have been mixed, however. 
 
Material and Methods Comparison of the N-glycan profiles of 5 rectal 
adenomas and 18 rectal carcinomas of different stages was by matrix-assisted 
laser desorption-ionization time-of-flight mass spectrometry. Tumour 
expression of REG4 and PODXL was evaluated by immunohistochemistry in 
840 consecutive CRC patients surgically treated between 1983 and 2001. In 
addition we evaluated in a subgroup of 220 consecutively surgically treated 
CRC patients the tumour expression of MUC1, MUC2, MUC5AC, 
synapthophysin, chromogranin, sialyl Lewis a (sLea), and pauci-mannose. All 
patients were treated at Helsinki University Hospital (HUH). 
Results Rectal adenomas and carcinomas can be distinguished from one 
another based on their N-glycosylation profile. Differences in N-glycosylation 
 
+!
existed also between carcinomas of different stages. Based on these results 
pauci-mannose and sLea were chosen for immunohistochemical analysis: in 
CRC sLea correlated with poor prognosis, and in advanced CRC, pauci-
mannose expression correlated with poor prognosis. PODXL was an 
independent marker of poor prognosis in CRC. The two antibodies showed 
similar prognostic profiles, but their staining patterns differed, and they 
recognized different groups of patients with a poor prognosis. Combination of 
the two PODXL antibodies identified a group of patients with even worse 
prognosis. REG4 expression associated with MUC1, MUC2, and MUC5AC 
expression in CRC and was a marker of favourable prognosis in non-mucinous 
CRC. 
 
Conclusion Mass spectrometry identified several carcinoma-related glycans 
and a method of transforming these results into immunohistochemistry was 
demonstrated.  PODXL was a marker of poor prognosis in CRC, whereas 
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3. ABBREVIATIONS 
 
ACF   Aberrant crypt foci  
APCC  Australian Clinico-Pathological Staging 
AJCC  American Joint Committee on Cancer 
APC  Adenomatous polyposis coli 
CIMP  CpG Island Methylator Phenotype  
CIN  Chromosomal instability 
CRC  Colorectal cancer 
CRM  Circumferential Resection Margin 
CT  Computed tomography 
DNA  Deoxyribonucleic acid 
DSS   Disease-specific survival 
EGFR  Epidermal growth facro receptor 
F  Deoxyhexose 
FAP  Familial adenomatous polyposis 
FIT  Faecal immunochemical blood test 
FOBT  Faecal occult blood testing  
FS  Flexible sigmoideoscopy  
G  N-glycolylneuraminic acid 
H  Hexose 
HNPCC  Hereditary non-polyposis colorectal cancer 
HUH  Helsinki University Hospital 
IHC  Immunohistochemistry 
kDa  Kilo dalton  
KRAS  Kirsten rat sarcoma viral oncogene homologue 
LHC  Left hemicolon 
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mAb  Monoclonal antibody 
MALDI-TOF Matrix-assisted laser desorption-ionization time-of-
flight 
MS  Mass spectrometry 
MSI Microsatellite instability 
MRI  Magnetic resonance imaging 
MUC  Mucin 
N  N-acetylhexosamine 
N-glycan   Asparagine-linked glycan 
P  Acid ester  
pAb  Polyclonal antibody 
PCA   Principal component analysis 
PODXL  Podocalyxin 
REG4  Regenerating islet-derived gene 4 
RHC  Right hemicolon 
RNA  Ribonucleic acid 
S  N-acetylneuraminic acid 
sLea  Sialyl Lewis a 
TIL  Tumour-infiltrating lymphocyte 
TMA   Tissue microarray 
TME  Total mesorectal excision 
TNM  Tumour node metastasis 
UICC  Union Internationale Contre le Cancer 
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4. INTRODUCTION 
 
Colorectal cancer is one of the world’s three most common cancers, and its 
incidence is rising. A great majority of CRCs are sporadic, while 4 to 5% of 
them result from hereditary syndromes, and the estimate is that up to 20% of 
colorectal cancers may have some familial component. Early detection, radical 
surgery, and adjuvant chemotherapy are important for clinical outcome. The 
most crucial factor today for predicting patient outcome is stage of disease at 
diagnosis; roughly 40% have localised disease and another 40% regional 
disease. (1) 
 
Adjuvant therapy is today standard care for Stage III patients, giving an 
absolute 10% increase in 5-year overall survival, but for Stage II patients, the 
benefit of adjuvant therapy is still unclear. In Stage II patients, T4-stage, high 
histological grade, vascular invasion, tumour obstruction, bowel perforation, 
and inadequate lymph node resection favour the need for adjuvant therapy, 
although only limited prospective data support this need. It would be important 
to identify those Stage II patients who benefit from postoperative treatment. (2) 
 
Because many of the tumour markers studied over the years, CA19-9, CA50, 
CA242, and STn, represent changes in the  carbohydrate structures of cancer 
cells, the N-glycan profiles in CRC are an interesting study subject. Glycans are 
the carbohydrate units of glycoproteins, glycolipids, and proteoglycans. 
Glycosylation evolves during carcinogenesis, meaning that carcinoma-related 
glycan structures are potential cancer biomarkers that can be detected by mass 
spectrometry (MS). To date, however, cancer-related carbohydrates have not 
been systematically screened by glycomic approaches, mainly due to lack of 
 
%'!
suitable analysis technologies. The prognostic role of glycan structures can be 
studied by MS or they can be translated into immunohistochemical methods by 
finding/producing relevant antibodies. 
 
In addition, the prognostic role of two glycoproteins in CRC was studied: 
podocalyxin (PODXL) and the regenerating islet-derived gene (REG) 4. 
PODXL is a transmembrane glycoprotein whose aberrant expression or allelic 
variation or both associate with poor prognosis and unfavourable 
clinicopathological characteristics in various cancers. REG4 belongs to a group 
of small secretory glycoproteins involved in cell proliferation and regeneration; 
it is up-regulated in inflammatory bowel diseases and also in gastrointestinal 
cancers. Reports on the association of REG4 expression with CRC prognosis 
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5. REVIEW OF THE LITERATURE 
5.1. Epidemiology 
Colorectal cancer is among the three most common cancers in both sexes, 
accounting for 1 in every 10 tumour types globally, with over 1.3 million new 
cases annually. It is the fourth most common cause of cancer death, with over 
600 000 deaths. Its incidence is 1.4-fold higher in men and between different 
regions, the difference in incidence is 10-fold. (3) 
 
CRC incidence has been rising in areas where it used to be low, while in 
Western Europe, Northern America, Australia, and New Zealand its incidence 
has reached a steady level or even decreased. (4). In Finland its incidence is still 
rising, with 2012 seeing new cases diagnosed amounting to approximately 
2900. CRC is the third most common cancer in Finland with only breast cancer 
in women and prostate and lung cancer in men having higher incidences. Over 
60% of CRC originate in the colon (5). The growing incidence of CRC in 
traditionally low-risk areas reflects a change in lifestyle and environmental 
factors, such as obesity, decreased physical activity, smoking, red-meat 
consumption, and high alcohol consumption.  
 
The mortality rate from CRC in Western countries has declined, often 
accredited to cancer screening programs, to early detection of cancerous 
lesions, and to availability of improved therapies. In Finland, male mortality 
from CRC in 2012 was 9.9 of 100 000, making it the third most common cause 
of cancer death. Female mortality from CRC was 6.9 of 100 000, making it, 
similarly,  the third most common cause. In 2012 in Finland, about 1200 
individuals died from CRC.  The cumulative 5-year survival of colon cancer 
 
%#!
was 61% for female and 60% for male patients, and that of rectal cancer 65% 
and 62%. (5) 
 
5.2. Etiology 
Risk factors for colorectal carcinogenesis include family history of colorectal 
neoplasias and development of polyps.  Chronic inflammation of the bowel, 
including ulcerative colitis and Crohn’s disease, is another risk factor for CRC. 
Long-standing inflammation and repair is proposed to change the cellular 
features of the epithelium and cause DNA damage (6); 10 years of ulcerative 
colitis elevates the risk for CRC 10- to 30-fold.  Patients with Crohn’s disease 
are at around 1.5-fold as high a risk for CRC than is a matching population (7). 
Diets with high caloric intake, meat, high animal-fat intake, and especially 
products of pyrolysis cause increased  risk for CRC, whereas diets rich in fruits, 
vegetables, and fibre reduce the risk (8). Alcohol consumption and smoking 





About 4 to 5% of all colorectal cancers result from hereditary syndromes, with 
the rest being sporadic; estimates are, however, that up to 20% of all colorectal 
cancers may have some familial component.  A model by Fearon & Vogelstein 
(11) has been the paradigm of genetic alterations during colorectal 
carcinogenesis. This model is based on colorectal carcinogenesis in familial 
adenomatous polyposis; in sporadic cases the pattern and order of mutations 
varies more.  
!
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Aberrant crypt foci (ACF), located in the mucosal crypts, are considered to 
contain the earliest premalignant genetic mutations and to be precursor lesions 
to adenomas and carcinomas (12). The vast majority of colorectal cancers arise 
through adenomas, but it is hypothesized that ACF can also transform directly 
into cancer(11,13). The adenoma-carcinoma pathway is a slow process, a time 
period measured in years, even decades. Time to progression depends on the 
adenoma’s qualities: large size, multiple adenomas, villous histology, and high-
grade dysplasia considered high-risk (14).  As a distinct entity among adenomas 
are the sessile serrated adenomas, thought to progress via a different pathway, 
with distinct molecular and pathological characteristics (15). 
 
 
Similar to other cancers, CRC is considered to arise after accumulating 
mutations in tumour-suppressor genes and oncogenes, leading to dysregulation 
of cell homeostasis and transitions of normal cells to cancerous ones. Based on 
sequential analysis of the colon cancer genome, a mean of 67 genes are mutated 
in the genome of a CRC, and a subset of 12 key genes have been proposed as 
those most likely to be involved in formation of an individual carcinoma (16). 
Three major pathways of genetic instability are currently recognized: a 
chromosomal instability (CIN) pathway that accounts 70 to 85% of sporadic 
CRCs, a microsatellite instability (MSI) pathway that appears in 15% of 
sporadic CRCs, and the CpG Island Methylator Phenotype (CIMP) pathway 
that appears active in up to 20% of sporadic CRCs. These pathways are not 
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undifferentiated cells at the bottom of colonic crypts; this is thought to lead to 
formation of an adenomatous polyp. Subsequent mutations are suggested to 
participate in carcinogenesis by affecting genes that regulate signalling 
pathways (22).  
 
KRAS mutation promotes cell proliferation, transformation, and differentiation 
(23) and is considered an early event in carcinogenesis.  It is thought to relate to 
tumour size. KRAS is a downstream effector of EGFR, which through BRAF 
activates the MAPK pathway. KRAS mutation is more common in large 
adenomas (45-60%, >2 cm) and carcinomas than in small adenomas (9%, <1 
cm) (24).   
 
Inactivation of TP53 is considered a late event in carcinogenesis. Normally 
functioning p53 protein inhibits thel cell-cycle upon DNA damage, thereby 
providing time for DNA repair, and when irreparable genetic damage occurs, it 
induces pro-apoptotic genes (17). 
 
 
5.3.2. The microsatellite instability (MSI) pathway 
Microsatellites are short repeating sequences of DNA, ones vulnerable to errors 
during replication due to their repetitive manner. When functioning normally, 
the DNA mismatch repair system (MMR) recognises and instantly repairs these 
errors (25).  Defective MMR presents as microsatellite instability (MSI) (26). 
 
The majority of MSI CRSs occur sporadically due to DNA methylation of the 
MLH1 promoter, whereas MSI is caused by germline mutations in one of the 
MMR genes in the hereditary Lynch syndrome. Both sporadic and hereditary 
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MSI tumours have similar biology, but the precursor lesion in Lynch syndrome 
is a traditional adenoma, whereas the predominant precursor lesion in sporadic 
MSI is an SSA. (19). MSI tumours are associated with location in the proximal 
colon and are often poorly differentiated (27). Sporadic MSI tumours are also 
more common in women and in elderly patients (26). 
 
 
5.3.3. The CpG Island Methylator Phenotype pathway 
Changes in gene expression or function caused by amechanism not affecting 
DNA sequence, such as DNA methylation or histone modification, are called 
epigenetic alterations (25). 
 
Short sequences rich in CpG dinucleotide, commonly found the in promoter 
region of genes, are prone to DNA methylation.  Methylation of these regions 
causes loss of gene expression, and typical examples in CRC are APC and 
MLH1. Methylation silencing the MLH1 expression thus causes sproradic MSI 
(19,25,27).  Hypermethylation, evident in up to 20% of CRC, is called the CpG 
Island Methylator phenotype (CIMP). CIMP is associated with proximal 
location, old age, female sex, mucinous and poor differentiation, MSI, and 











mutated MMR gene is better than that of sporadic colorectal cancer (33). 
Because of the high lifetime risk for colorectal cancer, the recommendation is 
regular screening by colonoscopy (34). 
 
The second most common hereditary syndrome, causing 1% of all colorectal 
cancers, is familial adenomatous polyposis (FAP). This results from mutations 
in the APC gene, resulting in hundreds to thousands of adenomatous polyps in 
the colorectum. The lifetime risk for colorectal cancer is virtually 100% at the 
median age of 40 (35). 
 
5.5. Screening 
As transition from detectable adenoma to carcinoma may take at least a decade, 
and the transition of early invasive cancer to overt disease several years, CRC is 
a good candidate for cancer screening. Faecal occult blood testing (FOBT) is 
the most common test to screen for CRC and the only one recommended by the 
EU (36). FOBTs need to be done repeatedly to enhance sensitivity, either each 
or every other year, since CRCs bleed intermittently (37). Screening by FOBTs 
reduces relative risk for CRC mortality by 16% (38). Two tests are available: 
guaiac-based FOBT (gFOBT) and the faecal immunochemical blood test (FIT). 
FIT has a higher sensitivity but a lower specificity for late adenomas and 
carcinomas than does gFOBT (39).  Flexible sigmoideoscopy (FS), allows 
inspection and the extraction of tissue specimens from the distal colon, has 
reduced relative CRC mortality by 18 to 23% (40,41). No such effect emerged, 
however in one population-based study (42). Colonoscopy allows inspection 
and tissue sampling of the whole colon with a sensitivity and specificity of 
practically 100%, suggesting it to be the perfect screening tool. Colonoscopy 
!
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has reduced relative mortality from CRC by 40 to 60% (43). However, its high 




Among, common symptoms for CRC are altered bowel habits, anaemia, 
haemotochezia, but many patients lack these symptoms altogether. Signs of 
advanced disease are fatigue, weight loss, abdominal pain, and bowel 
obstruction or perforation. Liver enlargement and ascites are symptoms of 
metastatic disease. (44) 
 
5.6.2. Diagnosis 
Clinical rectal examination can detect over half of all rectal tumours (45), but 
only large colonic tumours are palpable.    
 
In standard practise diagnosis is based on endoscopy, preferably total 
colonoscopy. This allows precise localisation and biopsy of the lesion, detection 
of possible synchronous cancerous or precancerous lesions, and removal of 
polyps. If a complete preoperative colonoscopy is for some reason impossible, 
then virtual colonoscopy or CT colonography are possible substitute options. If 
not carried out preoperatively, then a complete colonoscopy is recommended 3 
to 6 months after the operation. In rectal cancer, a rigid rectoscopy may enable  
evaluation of the position of the lowest part of the tumour relative to the anal 
canal, allowing the choice of an appropriate surgical technique. 
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5.6.3. Preoperative staging 
Preoperative clinical examination, instrumental screening, and laboratory tests 
can detect or exclude metastatic disease. Liver enzymes are usually screened 
preoperatively, although they can be normal even in the presence of liver 
metastases. Computed tomography (CT) of the abdomen is performed to allow 
detection of metastatic spread to the liver, and it also helps in the evaluation of 
tumour size, location, relationship to adjacent organs, and invasion depth. The 
sensitivity of CT for lymph node metastasis is 76% and specificity 55%, and for 
detection of distant metastases 85% and 98%. Chest CT is the first choice in a  
search for lung metastases (46). Routine use of positron emission tomography 
(PET) is not recommended at the time of diagnosis, because in the great 
majority of patients it does not modify the treatment approach (47). 
 
In addition to chest and abdomen CT, magnetic resonance imaging (MRI) 
serves for local preoperative staging in rectal cancer. MRI allows evaluation of 
depth of invasion, enlargement of lymph nodes, and distance of the tumour 




To improve patient prognosis, CRC treatment should involve multidisciplinary 
teamwork (48).  
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5.7.1. Surgical and preoperative treatment 
5.7.1.1. Colon cancer 
Tumour location determines the choice of operative technique: tumours from 
the caecum to the ascending colon are operated on by right hemicolectomy, 
tumours from the hepatic flexure to the right side of tranverse colon by 
extended right hemicolectomy, tumours from the left side of the tranverse colon 
to the splenic flexure by extended left hemicolectomy, and tumours from the 
descending colon to the sigmoid by left hemicolectomy. A proximal and distal 
margin of at least 5 cm is recommended, and en-bloc excision of the mesocolon 
with proximal ligation of the vessels improves radicality in locally advanced 
disease and improves staging. Invasion of the tumour into neighbouring organs 
requires en-bloc removal with healthy-tissue margins. On some occasions, local 
and small tumours can be removed by endoscopic resection (49). 
 
Laparoscopic surgery for colon cancer has several short-term advantages over 
open laparotomy, such as smaller incisions, lower usage of analgetics, reduced 
operative trauma leading to faster restoration of gastrointestinal motility, and a 
faster return to full activity and work (50). In laparoscopically operated patients 
surgical morbidity and post-operative complications are lower (51). 
Oncological outcomes between laparoscopic and open surgery do not differ. 
(52) 
 
At HUH, all patients with suspected stage III to IV disease at diagnosis are 
discussed at a multidisciplinary colon cancer meeting including a GI surgeon, a 
liver surgeon, an oncologist, a radiologist, and a pathologist.  The treatment 
plan decided upon is then explained to the patient. 
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5.7.1.2. Rectal cancer 
The aim of rectal cancer surgery is to minimize risk for residual disease in the 
pelvis  that often causes disabling local recurrence, and at the same time to 
minimize possible acute and late morbidity. What is also important is as often 
as possible, to retain sphincter function (53). Total mesorectal excision (TME) 
is the gold standard for a rectal cancer operation: combined with a 
circumferential resection margin (CRM), it results in low recurrence rates and a 
good oncological outcome. (54) 
 
Laparoscopic surgery for rectal cancer has short-term benefits similar to those 
of open surgery, just as it has  in colon cancer (4,50). Oncological result are 
similar between laparoscopic and open surgery.(11,55,56) 
 
To reduce local recurrences, preoperative radiotherapy of 25GY in 5-GY 
fractions over 5 days followed by immediate surgery (TME) is recommended 
for most T3 and some T4 tumours (e.g. with only peritoneal involvement) and 
for tumours with lymph-node involvement.  Here, an option for short 
radiotherapy is a longer 50GY 1.8 GY/fraction with or without 5-FU. 
Preoperative radiotherapy is more effective and less toxic than is postoperative 
radiotherapy.  
 
For most locally advanced tumours: T3 with lymph-node growth to the 
mesorectal fascia and T4 with non-readily resectable growth to neighbouring 
organs, a longer radiotherapy of 50GY in 1.8-GY fractions with 5-FU-based 
chemotherapy is recommended, followed by surgery 6 to 8 weeks later. (50,57) 
 
!
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At HUH all rectal-cancer patients’ care is centralized in a rectal-cancer care 
unit. Each patient’s preoperative radiological images and histological samples 
are discussed at a multidisciplinary rectal cancer meeting including a GI 
surgeon, a liver surgeon, an oncologist, a radiologist, and a pathologist.  A 
treatment plan is then decided upon and then explained to the patient. 
 
5.7.2. Adjuvant treatment 
Adjuvant therapy aims to improve prognosis and reduce risk for recurrence, and 
in CRC it is routine for stage-III patients, in whom it provides a 10% absolute 
increase in 5-year survival. (2,51). For stage II, it is not the routine 
recommendation for unselected patients, since the benefit in overall survival is 
quite small. (2,52) Adjuvant therapy is only recommended for high-risk stage-II 
patients: T4 stage, lymph nodes sampling <12, poorly differentiated tumour, 
bowel obstruction or tumour perforation, and tumour with vascular or 
lymphatic or perineural invasion. A doublet schedule with oxaliplatin and a 
fluoropyrimidine is standard. (53,58) 
 
In rectal cancer, adjuvant therapy can be given to stage-III and high-risk stage-




5.7.3. Treatment of metastatic colorectal cancer 
Liver, lung, peritoneum, and other colonic segments are the most common sites 
for metastasis that can receive curative surgery based on metastasis size and 
location. At the time of their diagnosis, 10 to 20% of liver metastases can be 
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resected and of unresectable tumours 10 to 15% can be resected after 
oncological treatment (59). No difference exist in perioperative or long-term 
outcomes between simultaneous or staged resection of liver metastases and 
primary tumour (60). Lung metastases are rare at the time of diagnosis and only 
less than 5% of them can be curatively operated on, most often due to other 
metastases (61). 
 
At HUH, a patient with metastatic CRC with readily resectable metastases 
usually receives adjuvant therapy after surgery for 6 months as combination 
chemotherapy. If the metastases are not readily resectable, combination therapy 
continues for 3 months before possible surgery, and for at least another 3 
months after surgery. 
 
5.7.4. Palliative surgery 
In some patients, because of too-advanced local or systemic disease or poor 
overall condition, no surgical resection of the primary tumour can be 
recommended. Then an obstructive tumour can be treated by stenting the 
tumour, or by a decompressing stoma or with by-pass surgery.  
 
5.8. Prognosis 
During recent decades, prognosis of patients with colorectal cancer in many 
countries has improved. In high-income countries, 5-year relative survival is 
almost 65%, while in low-income countries remaining below 50%. Survival is 
higher for younger patients, and is higher for women than for men in younger 
patients. (62)  The age-standardised 5-year colon-cancer-specific relative 
survival ratio in 2007-2009 in Finland was 60% for men and 61% for women, 
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with corresponding figures of 62% and 65% for cancers of the rectum, 
rectosigmoid, and anus. (5).  
 
  
5.8.1. Clinocopathological prognostic factors 
5.8.1.1. Stage 
The most important prognostic factor is stage at diagnosis (63). The tumour 
node metastasis (TNM) staging system is now the one most commonly used, 
published first by the Union Internationale Contre le Cancer (UICC) in 1949 
(64). Later it was integrated into the staging system of The American Joint 
Committee on Cancer (AJCC), creating the now-used TNM classification, with 
its latest and 7th edition published in 2010. Another staging system is the older 
Dukes classification, first published in 1932 (65) for rectal cancer only,  
adapted for the colon and rectum by Astler and Coller in 1953 (66), modified 
by Turnbull in 1967 to include unresectable tumours and distant metastases 
(67), and again by Australian Clinico-Pathological Staging (ACPS) in 1982 
(68). In Dukes stage A, the tumour invades the submucosa or at most the 
muscularis propria, and in a stage B tumour invades into or through the bowel 
wall into the surrounding fat. In stage C there is local lymph node metastasis, 
and in stage D distant metastasis or local residual tumour after surgery.  
 
In  the TNM 7th classification of colorectal cancer, T represents tumour 
infiltration, N represents lymph-node involvement, and M stands for distant 
metastasis (Table 1).  The original TNM stage is based on preoperative 
information, but for planning surgical and oncological treatment, the choice is 




The pathology report should include a definition of tumour site and size, 
presence of tumour perforation, histological type and grade, extent of tumour 
invasion (T stage), resection margins, tumour deposits, lymphovascular or 
neural invasion, tumour budding, number of lymph nodes studied and possible 
lymph-node metastases (N stage), and the possible involvement of other organs 
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Table 1. TNM stages by UICC, 7th edition, 2010 
T – Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through muscularis propria into subserosa 
or into non-peritonealized pericolic or perirectal tissues 
T4a Tumour perforates visceral peritoneum 
T4b Tumour directly invades other organs or structures 
 
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 3 regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in 2–3 regional lymph nodes 
N1c Tumour deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal 
tissues without regional nodal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4–6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
 
M – Distant Metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one organ or site (for example, liver, lung, ovary, nonregional 
node) 
M1b Metastases in more than one organ/site or the peritoneum  
 
Reprinted from AJCC: Colon and rectum. In: Edge SB, Byrd DR, Compton CC, et al., eds.: 
AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 143-164. 
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, 
Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh  







Table 2. Survival according to modified Dukes´ and TNM stage  
Dukes+ Stage T N M 5-year 
survival* 
- 0 Tis N0 M0  










































































Reprinted from AJCC: Colon and rectum. In: Edge SB, Byrd DR, Compton CC, et al., eds.: 
AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 143-164. 
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, 
Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh  
Edition (2010) published by Springer Science and Business Media LLC, www.springer.com. 
+Additional information to the original table *data for 5-year disease-specific survival from (69) 
5.8.1.2. Grade 
Histological grade is based on glandular formation of the tumour. Histological 
grade is divided into four groups according to the WHO classification: well 
differentiated (1), moderately differentiated (2), poorly differentiated (3), and 
undifferentiated (4). Low grade predicts better prognosis (15).  
 
5.8.1.3. Histological type 
Over 90% of cololorectal carcinomas are adenocarcinomas, originating from 
epithelial cells of the colorectal mucosa (15). Mucinous adenocarcinoma is a 
subtype of adenocarcinoma, in which over 50% of the tumour consists of 
extracellular mucin. The prognostic role of mucinous differentiation compared 
to that of conventional adenocarcinoma varies between studies (70,71) Rare 
!
! ! "%! ! ! ! !"%!
types of colorectal carcinomas include signet-ring cell, medullary, 
adenosquamous, neuroendocrine, undifferentiated,  and small cell carcinomas 
(15). 
 
5.8.1.4. Tumour deposits 
Focal aggregates of adenocarcinoma located in the pericolic or perirectal fat, 
discontinuous with the primary tumour, are called tumour deposits. Their origin 
is heterogenous, and they represent venous invasions, lymphatic invasion, 
nerve-sheath invasion, and continuous growth.  (72,73). They are more 
common in T3N+-disease than in local disease and indicate poor prognosis 
(74). 
 
5.8.1.5. Lymphatic, vascular, and perineural invasion 
Invasion of the tumour into extramural veins means increased risk for hepatic 
metastasis (75) and vascular invasion is a marker of poor prognosis (76). 
Tumour invasion into lymphatic vessels indicates poor prognosis (77), as does 
perineural invasion as well (78).  
 
5.8.1.6. Tumour immunity 
A high density of tumour-infiltrating lymphocytes (TILs) is associated with 
good prognosis, and low levels with poor prognosis (79) TILs are associated 
with the MSI-H phenotype, thought to result from the existence of frameshift 





5.8.1.7. Tumour budding 
Tumour budding is defined as cluster of undifferentiated cells detaching from 
the surrounding tumour at the CRC invasive edge (81). It is thought to represent 
epithelial to mesenchymal transition, to represent an early event in invasion and 
metastasis, and to be a factor indicating poor prognosis (82). 
 
5.8.1.8. Surgical margins  
In rectal cancer when TME is performed, in addition to proximal and distal 
margins of resection, the margin around the mesorectum  (CRM) is highly 
important. A positive CRM means elevated local recurrence rates and poorer 
survival when present in the rectal margins (83,84). In rectal cancer, CRM 
between 1 and 2 mm and for colorectal cancer distal margin of 2 cm, and 
proximal margin of 5 cm are considered adequate (85). 
 
 
5.9.1.9. Emergency surgery 
Between 15 and 30% of CRCs present as a surgical emergency, with most 
caused by obstruction (78%) or perforation (10%) (86,87). Patients who 
undergo emergency surgery tend to more often have metastases and have a 
higher T- and N-stage, also with vascular and perineural invasion often seen 
(88).Their overall survival is poorer for those patients needing emergency 
surgery than for patients with elective surgery (89,90). 
 
5.8.1.10. MSI  
Analysis of microsatellite instability (MSI) allows identification of patients 
with hereditary CRC, but it also has prognostic and predictive implications. The 
MSI status of CRC patients is usually stratified into two classes based on the 
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number of unstable loci: MSI high (MSI-H) and MSI low/MSI stable (MSI-
L)/MSS). MSI-H patients have a better overall survival (91) and MSI status 
also may prove useful as a predictive marker as well (62).  
 
5.8.1.11. Inflammatory colorectal cancer 
In addition to tumour characteristics also host-response factors determine 
prognosis (92). The host’s immune system plays a prognostic role in various 
cancers. These responses can be examined by the circulating concentrations of 
acute-phase proteins.  A systemic inflammatory response has been a sign of 
poor prognosis in CRC (93,94) and in other cancers (95). Glascow Prognostic 
Score, comprising albumin and C-reactive protein, is an independent marker of 
poor prognosis in CRC (96). 
 
5.9. Glycans 
Glycans, the carbohydrate units of glycoproteins, glycolipids, and 
proteoglycans, cover all human cells. Six main families of glycans exist: (1) 
asparagine-linked (N-linked) glycans of many glycoproteins, (2) serine-or 
threonine-linked (O-linked) glycans predominating on glycoproteins and 
membrane-bound mucins, (3) the glycosaminoglycans that present as free 
polysaccharides or as part of proteoglycans, (4) the glycosphingolipids 
consisting of oligocosaccharides binding to ceramide, (5) the 
glycosylphosphatidylinositol (GPI)-linked proteins (proteins bearing a glycan 
linked to phosphatidylinositol, and (6) various cytoplasmic and nuclear proteins 




Around 1% of the human genome participates in the biosynthesis of glycans 
(98-100).  
 
This biosynthesis is the most complex post-translational modification of 
proteins, and the great variability in glycan structures means a tremendous 
ability to fine-tune the glycoproteins’ chemical and biological properties. This 
glycosylation process occurs most abundantly in the Golgi apparatus and the 
endoplasmic reticulum, but also occurs in the cytoplasm and the nucleus 
(101,102). A majority of glycoconjugates are localized to cell surfaces, where 
glycans participate in events essential for cell viability and function, such as 
cell adhesion, motility, and intracellular signalling (102,103).  Changes in these 
functions are essential steps seen when cells transform into malignant ones, and 
these are also reflected in changes of a cell’s glycan profile, observed in many 
cancers (104-106). Specific structural changes in glycans may serve as cancer 
biomarkers (104,107-109), and changes in glycosylation profiles are related to 
tumours cells’ aggressive behavior(110-112). The incorporation of foreign 
monosaccharides from the environment has been proposed to promote 
carcinogenesis through systemic inflammation, as is the case of incorporation 




Cancer-associated N-glycan structures may play specific roles in supporting 
tumour progression: growth (114,115), invasion  (116,117), and angiogenesis  
(118). Changes in the N-glycan profile emerge in various cancers, including 
lung (119,120), breast (121), and colorectal cancer (120,122). Moreover, serum 
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N-glycosylation profiles from patients with CRC and those of healthy controls 




5.10.1. Serum markers  
Carcinoembryonic antigen (CEA) is a serum glycoprotein that participates in 
carcinoma cell adhesion, promoting tumour-cell aggregation, and possibly 
promoting metastasis (124). CEA is overexpressed by several 
adenocarcinomas: colorectal, breast and lung (125). Smokers have higher 
serum-CEA levels than do non-smokers, with elevation of serum CEA levels 
seen in various acute and chronic inflammations (126) and in cholestasis (127). 
Elevated CEA levels occur in 20% of CRCs (128). Preoperative CEA has some 
prognostic value (129), but in the clinic it is used for follow-up.  Increasing 
CEA levels in follow-up predict recurrence/metastasis, and including CEA 
measurements in follow-up improves prognosis (130,131). 
 
 
5.11. Tissue biomarkers in this thesis 
5.11.1. Podocalyxin 
The discovery of podocalyxin-like 1 (PODXL) was originally in kidney 
podocytes (132), but it is also expressed by vascular (133) and breast 
epithelium (134), and haematopoietic progenitors (135). It is an anti-adhesive 
type I transmembrane glycoprotein able to undergo extensive sialylazation and 
O-glycosylation. Estimated peptide mass for PODXL is 59kDa, and 
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prostranslational processing yields a mature glycoprotein of 165kDa (136). 
PODXL is recognised as a stem cell marker (137) and  is closely related to 
CD34 and endoglycan. Through its connections to intracellular proteins and to 
extracellular ligands, it participates in regulation of cell morphology and 
adhesion (138-141). The role of PODXL in cancer is not thoroughly 
understood, but it is thought to participate in epithelial-mesenchymal transition 
(142), and interact with various mediators of metastasis (139-141,143,144).  
 
In various cancers, such as renal cell carcinoma, breast, colorectal, urothelial 
bladder, testicular, and pancreatic cancer, PODXL has been reported to be 
expressed aberrantly, and in the first four also has been an independent marker 
of poor prognosis (134,139,145-148). Membranous PODXL expression has 
been suggested to correlate, in CRC and urothelial bladder cancer, with poor 
prognosis (146,147,149). Association of germline variants of PODXL with 
development of prostate cancer and also with a more aggressive form has been 
reported (143). Occurrence of missense mutations in PODXL elevates the risk 
for prostate cancer development of cancer by 50% and an in-frame deletion 




Regenerating islet-derived gene (REG) proteins represent a group of small 
secretory proteins involved in cell proliferation and regeneration, and also 
participating in formation of the immune system (98,100) . They belong to the 
calcium-dependent lectin (C-lectin) superfamily and based on their primary 
structure are divided into four families, REG I to IV. Distinctive of the other 
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REG proteins, REG4 binds polysaccharides independently of calcium (101).  
REG I to III genes are located on chromosome 2p12, while that of REG4 is on 
1p12-13. REG4 was first cloned and identified by Hartupee et al (103)  and by 
Kämäräinen et al (104).  REG4 contains a 158 amino acids, at a weight of 
18kDa, and it is physiologically expressed in the colon and the small intestine, 
with high expression in enteroendocrine cells (104,107).  In the gastrointestinal 
epithelium, REG4 is activated during specific phases of differentiation and 
maturation, its expression is spatially specific, and it has been suggested to 
support mucinous and neuroendocrine differentiation (98,100,150,151).  
 
Up-regulated REG4 expression occurs in inflammatory bowel diseases (IBD) 
(101,104) and also occurs in many malignancies: colorectal, gastric, and 
pancreatic cancers (103,152-154). REG4 participates in carcinogenesis and 
tissue regeneration, acts as an antiapoptotic factor, and promotes proliferation 
and invasion (104,155). Much still remains elusive as to REG4´s ultimate 
physiological and pathological roles. Expression of REG4 has predictive and 
prognostic value in many GI-tract cancers (104,107,152,153,156,157). The 
findings in CRC have been mixed: increased expression is, according to 
Numata et al (158), a sign of poor prognosis, whereas in other studies no 
association with  prognosis  has emerged (159,160). 
 
5.11.3. Mucins  
Mucins are high-molecular weight glycoproteins, defined by tandem repeat 
sequences with highly O-glycosylated serine and threonine residues (161). They 
are widely expressed by epithelial cells and are classified into membrane-
associated and secretory glycoproteins. Of the mucins studied here, MUC4 
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(mucin 4) and MUC5AC belong to secreted glycoproteins, while MUC1 and 
MUC2 are transmembranous (162). 
 
5.11.3.1. MUC1 
The MUC1 gene location is in chromosome 1q21, and MUC1 is expressed on 
the apical surfaces of secretory epithelial cells. During carcinogenesis, MUC1 
overexpression, aberrant glycosylation, and cytoplasmic localisation may play a 
role in anchorage-independent growth and resistance to apoptosis (162-164). In 
CRC, MUC1 expression is associated with mucinous phenotype, increased 




MUC2 is found predominantly in colorectal goblet cells; its expression has 
been proposed to decrease during CRC progression and to act as a marker of 
poor prognosis (167), but not all reports support this (168). 
 
5.11.3.3. MUC4 
MUC4, physiologically expressed in the epithelium of the respiratory, 
gastrointestinal, and genital tracts (169), is frequently overexpressed in CRC, 
where it associates with poor prognosis (170), but the mechanism regulating its 
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5.11.3.4. MUC5AC 
MUC5AC is mainly expressed in the tracheo-bronchial and gastric mucosa. In 
CRC its absence is associated with lower differentiation and poor prognosis. 
(171,172) 
 
5.11.4. Sialyl Lewis a 
Sialyl Lewis a (sLea), known in the clinic as CA19-9,  is a sialylated 
glycoconjugate found on the terminal chains of glycolipids and N-/O-
glycoproteins  (173,174)   Sialylation is a common phenomenon in 
glycoconjugates of malignant cells,  and overexpression of sLea is also seen in 
various carcinomas (175). As the ligand of E-and P-selectin (176),  sLea 
overexpression facilitates tumour angiogenesis and haemotogenous metastasis 
(177). This sLea overexpression appears concomitantly with loss of mucosal 
homeostasis and creation of tumour progression facilitating immune status 
(178,179). In CRC overexpression of sLea associates with neoplastic 
transformation and poor prognosis (178,180). The sLea antigens are released 
into the bloodstream; high serum levels of sLea associate with poor prognosis in 
CRC and other GI tumours (181). In clinical practise CA19-9, serves for 
diagnosis and follow-up of various malignancies, especially for pancreatic 
cancer, but for also CRC (129). 
 
5.11.5. Paucimannose  
Paucimannosidic N-glycan stuctures are rare in vertebrates. Paucimannose is a 
product of lysosomal exoglycosidases, whose high levels appear in CRC tissue 
as well as in serum (182,183). Paucimannose is up-regulated in CRC compared 
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to levels in healthy tissue (122), but its role in carcinogenesis is still very much 
unclear. 
 
5.11.6. Markers of neuroendocrine differentiation 
Poorly differentiated colorectal adenocarcinoma often retains the capacity for 
neuroendocrine differentiation (NED) (184). NED in CRC ranges from 12 to 
78%, most likely due to differing diagnostic markers and standards. In CRC 
NED is a marker of poor prognosis (185,186). Several biomarkers serve to 
diagnose NED, with different sensitivities and specificities; those most widely 
used are choromogranin a and synaptophysin.  
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6. AIMS OF THE STUDY 
 
• To discover the differences in N-glycosylation between rectal adenomas 
and carcinomas, and within carcinomas of different stages  
• To translate these glycomic result into prognostic evaluation by 
immunohistochemistry 
• To discover the association of PODXL with clinicopathological 
parameters and its role as an prognostic marker in CRC by two different 
antibodies 
• To discover the association of REG4 with clinicopathological 
parameters and other intestinal markers, and to evaluate its role as a 












7. PATIENTS AND METHODS 
7.1. Patients  (I-IV) 
All patients in the studies had undergone surgery at the Department of Surgery, 
HUH, and tissue samples were stored in the archives of the HUH Department 
of Pathology.  
 
The study population for immunohistochemistry comprised 840 consecutive 
colorectal cancer patients undergoing surgery in 1983-2001. (I-II, IV) A 
subgroup of 240 comprised consecutively operated patients from between 1998 
and 2001 (III-IV).  PODXL and REG4 were studied in the whole population; 
MUC1, MUC2, MUC4, MUC5AC, CA19-9, and paucimannose in the 
subgroup. The Finnish Population Register Centre provided the follow-up vital-
status data needed to compute survival statistics, and Statistics Finland provided 
cause of death for all those deceased. Median age at diagnosis was 66, with a 
median follow-up of 5.1 years  (range 0-25.8).  The 5-year disease-specific 
survival rate was 58.9% (95%Cl 55.0-62.8%).  For the subgroup, median age at 
diagnosis was 67 with a median follow-up of 6.0 years  (range 0-13.2).  The 5-
year disease-specific survival rate was 64.8% (95%Cl 58.1-71.5%). Table 3.  
!
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Table 3. Clinicopathological characteristics of the study population for 
immunohistochemistry 
Adapted from publication IV, permission by CC BY. 
 
 Study population 1983-2001 Subgroup of  1998-2001 
n (%) 840 220 
Age. years   
<65 360 (42.9) 101 (45.9) 
"65 480 (57.1) 119 (54.1) 
Gender   
Male 466 (55.5) 134 (60.9) 
Female 374 (45.5) 86 (49.1) 
Dukes   
A 125 (14.9) 34 (15.5) 
B 294 (35.0) 71 (32.3) 
C 231 (27.5) 70 (31.8) 
D 190 (22.6) 45 (20.5) 
Grade (WHO)   
1 29 (3.5) 8 (3.7) 
2 571 (68.4) 165 (76.7) 
3 202 (24.2) 37 (17.2) 
4 33 (4.0) 5 (2.3) 
Missing 5 5 
Side   
Right 227 (27.0) 50 (22.7) 
Left 613 (73.0) 170 (77.3) 
Location   
Colon 429 (51.1) 87 (39.5) 
Rectum 411 (48.9) 133 (60.5) 
Histology   
Adenomatous 749 (89.3) 208 (95.0) 
Mucinous 90 (10.7) 11 (5.0) 




For MS (III) analysis we chose 18 rectal carcinoma patients (4 each at stages I-
III and 6 at stage IV) and 5 rectal adenoma patients. All selected cases were 
blood group A Rh+ in order to minimize the possible influence of blood group 
antigens on glycan profiles. Detailed patient characteristics are in Table 4. 
 
 
Table 4. Description of the sample cohort for mass spectrometry 
aDukes A-D, bTNM, tumor node metastasis, cAge at diagnosis, Adeno=Adenocarcinoma, 
G=Grade(1-4, WHO). Adapted from Study III, permission by CC BY.  
Stagea TNMb Sex Agec Tumour size(cm) Tumour histology 
Adenoma F 84 Large Severe dysplasia 
Adenoma F 79 Large Severe dysplasia 
Adenoma F 72 2 Severe dysplasia 
Adenoma M 64 10 Severe dysplasia 
Adenoma  M 52 2 Severe dysplasia 
A T2N0M0 F 49 4 Adeno, G1 
A T2N0M0 M 59 3 Adeno, G2 
A T2N0M0 M 59 14 Adeno, G2 
A T2N0M0 M 53 2 Adeno, G2 
B T3N0M0 M 87 5 Adeno, G2 
B T3N0M0 M 71 7 Adeno, G2 
B T3N0M0 F 76 7 Adeno, G2 
B T3N0M0 M 56 5 Adeno, G2 
C T3N1M0 M 74 3 Adeno, G2 
C T3N1M0 M 61 4 Adeno, G2 
C T3N1M0 F 55 5 Adeno, G2 
C T3N2M0 M 84 4 Adeno, G2 
D T3N1M1 F 56 7 Adeno, G2 
D T3N2M1 M 82 5 Adeno, G2 
D T3N2M1 M 66 5 Adeno, G3 
D T4N2M1 M 28 6 Adeno, G3 
D T3N1M1 M 50 5 Adeno, G3 
D T3N2M1 F 64 3 Adeno, G3 
!
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7.2. Tumour tissue specimens  (I-IV)!
Formalin-fixed and paraffin-embedded tumour samples were obtained from the 
archives of the Department of Pathology, HUH. An experienced pathologist 
marked representative areas of tumour samples on haematoxylin- and eosin-
stained tumour slides.  Three 1.0-mm-diameter punches from each sample were 
mounted on recipient paraffin blocks with a semiautomatic tissue microarray 
instrument (Beecher Instruments, Silver Spring, MD,USA) as described (187) 
 
7.3. Production of monoclonal PODXL antibody HES9 (I) 
For the novel monoclonal antibody (mAb) HES9 used in Study I, immunization 
of mice was with the undifferentiated human embryonic (hES) stem cell line 
SA167 (Cellartis, Göteborg, Sweden, www.cellartis.com). By conventional 
hybridoma technology, hybridoma cell lines were established to produce mAbs 
against hES cells. Mimotope analysis, immunoprecipitation, and mass-
spectrometry identified the target antigen as podocalyxin. For a detailed 
description see Supplementary file 1 of Study I. 
 
7.4. Immunohistochemistry (I-IV) 
First, the tumour tissue microarray blocks were freshly cut into 4-!m sections, 
fixed on slides, and dried at 37°C for 12 to 24 hours.  After deparaffinization in 
xylene and rehydration through a gradually decreasing concentration of ethanol 
to distilled water, slides were treated in a PreTreatment module (Lab Vision 
Corp., Fremont, CA, USA) in antibody-specific buffer for 20 min at 98°C for 
antigen retrieval. Staining of sections was performed in an Autostainer 480 
(Lab Vision) by the Dako REAL EnVision Detection system, 
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Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup, Denmark). Tissues were 
incubated with the chosen antibody for one hour at room temperature. 
Antibodies and variations in pre-treatment, dilution, and positive control are in 
Table 5. 
 
Table 5. Antibodies for immunohistochemistry 
Antibody Clone Company Pre-treatment Dilution Positive 
control 
PODXL HES9 mAb In-house Tris-HCl (pH 8.5) 1:500 Kidney 
PODXL 
HPA002110 
pAb Atlas Antibodies Tris-HCl (pH 8.5) 1:250 Kidney 
CA19-9/sLea mAb,NCL-
L-CA19-9 
Novocastra, UK Tris-HCl (pH 8.5) 1:300 Colon 
Paucimannose mAb a Tris-HCl (pH 8.5) 1:100 Colon 
REG4  mAb b Tris-HCl (pH 8.5) 1:50 Colon 
MUC1 mAb, 
Ma552 
Novocastra, UK Citrate (pH 6.0) 1:25 Stomach 
MUC2 mAb, 
Ccp58 
Novocastra, UK Citrate (pH 6.0) 1:100 Colon 





Novocastra, UK Citrate (pH 6) 1:50 Stomach 
Synaptophysin mAb 
27G12 
Novocastra, UK Tris-EDTA(pH 
9.0) 
1:200 Colon 
Chromogranin mAb, 5H7 Novocastra, UK Tris-EDTA(pH 
9.0) 
1:2000 Colon 




7.5. Scoring of samples (I-IV) 
Tumour specimens were scored independently by two researchers who were 
blinded to clinical data and outcome. Differences in scoring were discussed 
until consensus. With all antibodies, the highest score of the triplicates of each 
sample was considered representative for analysis. 
!
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In Study I, PODXL expression by mAb HES9 was mainly cytoplasmic, with 
membranous positivity only seen with strong cytoplasmic staining. It was 
scored as negative cytoplasmic staining as 0, weakly positive as 1, moderately 
positive as 2, and strongly positive as 3.  
  
In Study II, PODXL expression by pAb HPA002110 was cytoplasmic in 
tumour cells, but in some cases a distinct membranous expression was visible, 
which did not always correlate with intensity of cytoplasmic expression. 
Expression scoring: cytoplasmic staining as 0-2 (negative-moderate-strong) and 
in case of distinct membranous staining as 3, regardless of the intensity of the 
cytoplasmic staining. 
  
In Study III, sLea and paucimannose expression were cytoplasmic and scored as 
negative-low-moderate-high (0-3) 
  
In Study IV, REG4, MUC1, MUC2, MUC4, MUC5AC, synaptophysin, and 
chromogranin expressions were cytoplasmic and scored as follows: REG4 
cytoplasmic expression was scored in tumour cells as either negative or 
positive. MUC1 and MUC2 expressions were cytoplasmic in tumour cells and 
were scored as negative-low-moderate-high (0-3) according to intensity. 
MUC4, MUC5AC, synapthopysin, and chromogranin cytoplasmic expressions 





7.6. Glycan isolation (III) 
Glycans were detached from cellular glycoproteins by PNGase F digestion 
(Prozyme, Hayward, CA, USA). First, soluble contaminants were removed by 
precipitating the proteins with ice-cold 75% ethanol at -20°C. Precipitated 
proteins were recovered by centrifugation, followed by PNGase F digestion to 
the protein pellet in 20 mM sodium phosphate buffer pH 7.3 in overnight 
digestion. The detached glycans then passed in water through Hypersep C18 
(Thermo Scientific, Waltham, MA, USA) and were absorbed to Hypersep 
Hypercarb 50mg (Thermo Scientific), both in a 96-well format. The carbon 
wells were washed with water, and neutral glycans were eluted with 25% 
acetonitrile in water (v/v); and acidic glycans with 0.05% (v/v) trifluoroacetic 
acid in 25% acetonitrile in water (v/v). The acidic glycans were further purified 
by being adsorbed first to MassPREPTM HILIC !Elution Plate (Waters, 
Milford, MA, USA) in 90% acetonitrile, and eluting by 50mM NH4HCO3. Both 
glycan fractions were additionally passed in water through strong cation-
exchange resin (Bio-Rad Laboratories, Hercules, CA, USA) and C18 silica resin 
(Millipore, Billerica, MA, USA). 
 
7.7. Mass spectrometry (III) 
Mass spectrometry (MS) is based on the separation of ions from a sample, 
according to their mass-to-charge ratio (m/z), and then recording their relative 
abundance. First, the compound is transformed into the gas phase by electron 
ionization. These molecular ions then undergo multiple fragmentations.  The 
ions produced are then separated according to their mass-to-charge ratio and 
their abundance recorded, producing the mass spectrum of the compound.  
 
!
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7.7.1. MALDI-TOF in this study 
Matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass 
spectrometry was performed by a Bruker Ultraflex III TOF/TOF instrument 
(Bruker Daltonics Inc, Bremen, Germany).Acidic N-glycans in negative ion 
linear mode as [M - H]- ions and neutral N-glycans were detectable in positive 
ion reflector mode as [M + Na]+ ions. Relative molar abundances of neutral and 
acidic glycan components were assigned based on their relative signal 
intensities in the mass spectra when analyzed separately as the neutral and 
acidic N-glycan fraction. The mass spectrometric raw data underwent 
transformation into the present glycan profiles by removal of the effect of 
isotopic pattern overlapping, multiple alkali-metal adduct signals, products of 
elimination of water from reducing oligosaccharides, and other interfering mass 
spectrometric signals not arising from the sample similarly as described (190). 
Resultant glycan signals in the glycan profiles were normalized to 100% to 
allow relative quantitative sample comparison. The glycan signals were then 
assigned to biosynthetic groups based on their proposed monosaccharide 
composition (120,190), see Supplementary table 1 of Study III. 
 
7.8. Statistical analysis  
7.8.1. For mass spectrometry (III) 
The mean values of the relative intensities of N-glycan signals of each patient’s 
paired samples served for statistical analyses. Mean relative intensities and the 
error of means of all N-glycan signals from the whole study group were 
calculated for neutral and acidic glycans separately. The Mann-Whitney test 
served to compare differences in glycomic structures between adenomas and 
carcinomas, and between carcinomas of different stages. When a statistically 
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significant difference was seen by the Mann-Whitney test, then also the mean 
of glycan structures’ relative amounts, the standard errors of the mean, and the 
fold change of the means between groups were calculated. Error propagation 
served to assess standard error for the fold change. For principal component 
analysis (PCA), the relative intensities of structures were used, whose relative 
intensities differed significantly, by the Mann-Whitney test, between adenomas 
and carcinomas. Two components were extracted for both neutral and acidic N-
glycans. Bartlett’s test showed whether the correlation matrix was identity 
matrix, and the Kaiser-Meyer-Olking test served to test the adequacy of PCA 
for the data. 
 
7.8.2. For immunohistochemisty (I-IV) 
Immunohistochemical expressions were dichotomized for statistical purposes:  
PODXL mAb (low vs. high), PODXL pAb (non-membranous vs.membranous), 
REG4 (negative vs. positive), pauci-mannose (low vs. high), CA19-9 (low vs. 
high), MUC1 (low vs. high), MUC2 (low vs. high), MUC4 (negative vs. 
positive),  MUC5AC (negative vs. positive), synaptophysin (negative vs. 
positive),  and chromogranin (negative vs. positive). 
 
To study the two PODXL antibodies together required  a categorization with 
three classes: low (mAb=low and pAb=non-membranous), moderate (either 
mAb=high or pAb=membranous), and high  (mAb=high and pAb= 
membranous). Two similar categorizations were created to analyze REG4 and 
PODXL together:  R+Pm- (REG4=positive and PODXL mAb=low), R-or Pm+ 
(either REG4=negative or PODXL mAb=high), and R-Pm+ (REG4=negative 
and PODXL mAb=high). Second category: R+Pp- (REG4=positive and 
PODXL pAb=non-membranous), R-or Pp+ (either REG4=negative or PODXL 
!
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pAb=membranous), and R-Pp+ (REG4=negative and PODXL pAb= 
membranous). 
 
Evaluation of the association between biomarker expression and 
clinicopathological parameters was by the exact Pearson chi-square test or the 
exact linear-by-linear association test for ordered parameters.  Disease-specific 
overall survival was counted from date of surgery to date of death from 
colorectal cancer, or until end of follow-up. Survival analysis by the Kaplan-
Meier method was compared by the log rank test. The Cox regression 
proportional hazard model served for uni- and multivariable survival analysis, 
adjusted for sex, age, Dukes classification, and differentiation. Testing of the 
Cox model assumption of constant hazard ratios over time involved the 
inclusion of a time-dependent covariate separately for each testable variable. 
The hazard ratio of differentiation and Dukes D was analyzed in two periods 
with all biomarkers (0 to 1.25 and 1.25 to 5 years) in order to meet the 
assumptions of the Cox model, with the time-dependent Cox model. Interaction 
terms were considered. All tests were two-sided. A p-value of 0.05 was 
considered significant. All statistical analyses were done with SPSS version 









8.1. Neutral N-glycan profiles  
Figure 3A shows an overall comparison of MALDI-TOF mass spectrometric 
profiles of neutral N-glycans from rectal adenomas and carcinomas. The glycan 
compositions H5N2, H6N2, H7N2, H8N2 and H9N2, identified as high-
mannose type-N glycans, were the most abundant glycan signals of the neutral 
N-glycan fractions of both adenomas and carcinomas. However, in comparison 
to adenomas, the relative amount of the smallest high-mannose type glycan 
H5N2 was higher in all carcinoma stages compared to the other high-mannose 
glycans. Neutral complex-type N-glycans, most notably H3N4F1, H4N4F1, 
H5N4, and H5N4F1, were more abundant in carcinomas than in adenomas. The 
third notable group of neutral glycan signals in the present study was of pauci-
mannose type N-glycans, which were more abundant in carcinomas than in 
adenomas, glycans such as H2N2F1, H3N2, H3N2F1, and H4N2.  
 
8.2. Acidic N-glycan profiles 
Figure 3B shows the overall acidic N-glycan profiles of the sample group. In 
the acidic N-glycan profiles, the acid ester-containing structures were major 
glycans in adenomas but not in carcinomas, ones such as H5N4F2P1, 
H4N5F2P1, H5N4F3P1, and H4N5F3P1. Sialylated structures dominated the 
carcinoma acidic N-glycan profiles, for example the sialylated N-glycans 
S1H5N4F1 and S2H5N4F1. Larger sialylated N-glycans like S1H6N5F1 were 
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8.3. Glycosylation differences between adenomas and 
carcinomas 
Statistically significant changes in N-glycan structures were evident between 
adenomas and carcinomas (Figure 4A+B). A significant increase occurred in  
monoantennary-size structures for both acidic and neutral N-glycans in 
carcinomas compared to levels in adenomas. 
 
Sialylated structures were more common in carcinomas, whereas acid ester-
modified N-glycans were especially abundant in adenomas. Neutral complex- 
and hybrid-type N-glycans were also more common in carcinomas as evidenced 
in their significantly increased relative presence in the neutral N-glycan 
fraction. In carcinomas, we saw an increase, although statistically non-
significant, of pauci-mannose structures among neutral N-glycans. Glycan 
signals that could potentially contain sialylated Lewis-type structures were also 
higher in carcinomas than in adenomas, although this difference was 
statistically non-significant. All p-values and ratios of means are in 
Supplementary Table 2A and B of Study III. 
 
Principal component analysis, when the structures with statistically significant 
differences between adenomas and carcinomas (5 structure types in neutral N-
glycans and 6 in acidic N-glycan structures) were included, demonstrated that 
neutral N-glycans were homogenous in adenomas, but not in carcinomas. The 
profiles of carcinomas differed from those of adenomas, but they also differed 
among themselves (Fig 5A).  A similar phenomenon was apparent for acidic N-
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8.6. Immunohistochemistry (I-IV) 
With the PODXL mAb , PODXL stained evenly throughout the cytoplasm in a 
granular manner in the vast majority of tumours, and staining was visible in all 
tumour cells. Neither nuclear nor cell membranous immunopositivity occurred.  
PODXL expression by the pAb was cytoplasmic in tumour cells, but in some 
cases a distinct membranous expression was visible, which did not always 
correlate with intensity of cytoplasmic expression.  
 
REG4 expression in tumour cells was cytoplasmic and slightly granular. When 
present, expression was evident in the vast majority of tumour cells, but with no 
nuclear expression. In whole-tissue sections, no clear distinction in expression 
appeared between the invasive front and the rest of the tumour. Moreover, in 
whole sections, REG4 expression appeared in some cases in normal epithelium, 
but was down-regulated in tumour cells. Expression of mucins, synapthopysin, 
and chromogranin was cytoplasmic, with no nuclear expression. 
 
sLea expression was membranous with apical membrane predilection and 
partially cytoplasmic, but with no visible nuclear staining. Pauci-mannose 
expression was mostly cytoplasmic and often granular, with only minor 
membranous accumulation and no visible nuclear staining. Expression of each 




Table 6. Immunohistochemical expression of biomarkers in colorectal cancer 
Marker Patients N(%)    
PODXL mAb  Negative Weak Moderate Strong 
 767 41 (5.3) 430 (56.1) 252 (32.9) 44 (5.7) 
PODXL pAb  Negative Moderate Strong Membranous 
 780 46 (5.9%) 322 (41.2%) 349 (44.7%) 63 (8.1) 
REG4  Negative   Positive 
 793 580 (73.1)   213 (28.9) 
MUC1  Negative Weak Moderate Strong 
 206 80 (38.8) 90 (43.7) 27 (13.1) 9 (4.4) 
MUC2  Negative Weak Moderate Strong 
 210 143 (68.1) 31 (14.8) 19 (9.0) 17 (8.1) 
MUC4  Negative Weak Moderate Strong 
 208 106 (51.0) 77 (37.0) 17 (8.2) 8 (3.8) 
MUC5AC  Negative Weak Moderate Strong 
 205 191 (93.2) 9 (4.4) 1 (0.4) 4 (2.0) 
Synaptophysin  Negative   Positive 
 215 209 (97.2)   6 (2.8) 
Chromogranin  Negative   Positive 
 217 212 (97.7)   9 (2.3) 
Paucimannose  Negative Weak Moderate Strong 
 208 8 (3.8) 107 (51.4) 76 (36.5) 17 (8.2) 
sLea  Negative Weak Moderate Strong 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































y Pearson chi-square exact-test or linear-by-linear test for ordered param
eters. M








































































































































































































































8.7. Expression patterns of the two PODXL antibodies 
The agreement of expression of the two antibodies across cases was low 
(kappa-value=0.219, standard error 0.060, p<0.0001) using dichotomous values 
for both antibodies. The distinctive strong staining by mAb (n=44) and 
membranous staining by pAb (n=63) was shared by only 14 tumours. 
 
8.8. Association with clinicopathological variables (I-IV) 
The associations of PODXL, REG4, Pauci-mannose, and sialyl Lewis with 
clinicopathological paramateters were done by the exact Pearson test of linear-
by-linear test for ordered parameters (Tables 7 and 8). High cytoplasmic 
expression of PODXL by the mAb associated with low differentiation, 
advanced disease, and location in the right hemicolon. Results were similar for 
the membranous expression of PODXL by the pAb, but no association with 
right hemicolon was apparent. The combined expression of  both PODXL 
antibodies yielded results similar to those of the mAb. 
 
Positive cytoplasmic REG4 associated with local disease, mucinous histology, 
and location of the tumour in the right hemicolon. Cytoplasmic pauci-mannose 
expression associated with non-mucinous histology. sLea associated with poor 
differentiation. 
 
8.9. Association of REG4 with other biomarkers (IV) 
In the subgroup of 220 tumours, we found that REG4 expression significantly 
associated with higher expression of MUC2, MUC4, and MUC5AC, but not 
!
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with MUC1 expression. Nor did REG4 expression associate with markers of 
neuroendocrine differentiation (Table 9). 
 
Table 9. REG4 associates with MUC1, MUC2, and MUC4 expression in CRC 
*By Pearson chi-square exact-test or linear-by-linear test for ordered parameters. Missing data 
is not included in the analyses. Modified from publication IV, permission by CC BY. 
 
8.10. Association of PODXL with REG4 in CRC (unpublished 
data) 
Positive REG4 expression was associated with non-membranous PODXL 
expression by the pAb, but no association was apparent by PODXL expression 
by the mAb. With the combined PODXL expression, low expression associated 
with REG4 positivity. (Table 10) 
 
REG4 
 negative positive  
n (%) 162 (76.4) 50 (23.6) p-value* 
MUC1 
expression    
low 131 (84.0) 36 (78.3) 0.368 
high 25 (16.0) 10 (21.7)  
MUC2 
expression    
low 147 (93.6) 24 (48.0) <0.0001 
high 10 (6.4) 26 (52.0)  
MUC4 
expression    
negative 90 (57.0) 14 (29.2) 0.001 
positive 68 (43.0) 34 (70.8)  
MUC5AC 
expression    
negative 150 (96.2) 38 (82.6) 0.004 
positive 6 (3.8) 8 (17.4)  
Neuroendocrine 
differentiation    
negative 152 (93.8) 45 (90.0) 0.354 
positive 10 (6.2) 5 (10.0)  
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Table 10. Association of REG4 with PODXL in CRC 
 
*By Pearson chi-square exact-test or linear-by-linear test for ordered parameters. Missing data 
is not included in the analyses 
 
8.11. Univariable survival analysis 
8.11.1. Podocalyxin 
In CRC, Kaplan-Meier analysis showed significantly poorer disease-specific 
survival (DSS) for patients with high PODXL (by the mAb) expression 
(p=0.001) (Figure 8A). Five-year DSS was 42.5% for high PODXL expression 
(95% CI 27.2-57.8%) and 59.8% (95% CI 56.1-63.5%) for low expression. 
Because of the difference in the biological and anatomical background of the 
right and left colorectum, and also in expression pattern of PODXL (by mAb) 
results were also stratified for RHC vs. LHC.  For RHC cancer patients, no 
evidence of any difference in survival emerged between patients with high 
REG4 Expression 
 negative positive  
n (%) 580 (73.1) 213 (28.9) p-value* 
PODXL 
expression    
Low 506 (93.5) 188 (95.9) 0.22 
High 35 (6.5) 8 (6.1)  
missing 39 17  
PODXL 
expression    
Non-membranous 502 (90.3) 197 (96.1) 0.010 
Membranous 54 (9.7) 8 (3.9)  
Missing 24 8  
Combined 
PODXL     
Low 489 (86.4) 195 (92.9) 0.012 
Moderate 65 (11.5) 14 (6.7)  
High 12 (2.1) 1 (0.5)  
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8.11.3. PODXL and REG4 combined 
CRC patients with with concomitant negative REG4 expression and high 
PODXL expression (by mAb) had a poorer 5-year  DSS than did the (R+Pm-) 
group (p<0.0001) and (R-or Pm-) group (p=0.005).  No difference appeared 
between the latter two groups (p=0.092). The 5-year DSS was: (R-Pm+) group 
40.6% (95%CI 23.6-57.7), (R-or Pm-) group 58.5% (95%CI 54.2-62.8), and 
(R+Pm-) group 64.4% (95%CI 58.1-70.7). 
 
A similar effect was seen with concomitant negative REG4 expression and 
membranous PODXL expression (by pAb) compared to the (R+Pp-) group 
(p<0.0.0001) and (R-or Pp+) group (p=0.001). No difference appeared between 
the latter two groups (p=0.24). The 5-year DSS were: (R-Pp+)-group 37.3% 
(95%CI 23.0-51.6), (R-or Pp-) group 59.3% (95%CI 55.0-63.6), and (R+Pp-) 
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8.12. Multivariable survival analysis 
A Cox proportional hazard model adjusted for sex, age, Dukes classification, 
and differentiation served for multivariable survival analysis. In the 
multivariable models, higher stage, poorer differentiation, and age over 65 were 
independent markers of poor prognosis. 
 
High PODXL by the mAB  (Table 11A) and membranous PODXL expression 
by the pAb (Table 11B) were independent markers of poor prognosis in CRC 
(respectively ,HR 1.82, 95% CI 1.15-2.86, p=0.01; and HR 1.64, 95% CI 1.11-
2.43, p=0.012). Their combination was also an independent marker of poor 
prognosis (moderate vs low HR 1.63, 95% 1.11-2.39, p=0.012; and high vs low 
HR 2.14, 95% CI 1.12-4.07, p=0.021) (Table 11C). 
 
For non-mucinous-CRC patients under age 65, REG4 was an independent 
factor of favourable prognosis (HR 0.55, 95% CI 0.33-0.92, p=0.022) (Table 
11D). 
 
High CA19-9 expression was an independent marker of poor prognosis in CRC 
(HR 1.80, 95% CI 1.09-2.98, p=0.023) (Table 11E). 
 
!"#
Table 11.A Cox multivariable analysis of relative risk of death from non-
mucinous colorectal cancer within 5 years by REG4 expression for patients 
under 65 
  HR (95% CI) p-value 
REG4 expression   
Negative 1.00  
Positive 0.55 (0.33-0.92) 0.022 
Gender   
Female 1.00  
Male 0.97 (0.65-1.44) 0.865 
Stage   
Dukes A 1.00  
Dukes B 2.38 (0.68-8.37) 0.175 
Dukes C 6.16 (1.88-20.19 0.003 
Dukes D 30.65 (9.52-98.69) <0.0001 
Differentiation   
Grades 1-2 1.00  
Grades 3-4 (0-1.25y) 2.45 (1.32-4.55) 0.005 
Grades 3-4 (1.25-5.0y) 0.31 (0.13-0.76) 0.010 
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Table 11.B Cox multivariable analysis of relative risk of death from colorectal 
cancer within 5 years by PODXL expression by mAb HES9 
 
 HR (95% CI) p-value 
PODXL expression   
Low 1.00  
High 1.82 (1.15-2.86) 0.01 
Age   
!65 1.00  
>65 1.75 (1.38-2.23) <0.0001 
Gender   
Female 1.00  
Male 1.04 (0.82-1.31) 0.759 
Stage   
Dukes A 1.00  
Dukes B 2.51 (1.24-5.10) 0.011 
Dukes C 6.75 (3.38-13.46) <0.0001 
Dukes D (0-1.25y) 44.47 (21.22-93.18) <0.0001 
Dukes D (1.25-1.5y) 25.91 (12.54-53.54) <0.0001 
Differentiation   
Grades 1-2 1.00  
Grades 3-4 (0-1.25y) 1.92 (1.36-2.70) <0.0001 
Grades 3-4 (1.25-5.0y) 0.801 (0.53-1.20) 0.285 


















Table 11.C Cox multivariable analysis of relative risk of death from colorectal 
cancer within 5 years by PODXL expression by pAb HPA002110 
 
 HR (95% CI) p-value 
PODXL expression   
Non-membranous 1.00  
Membranous 1.64 (1.11-2.43) 0.012 
Age   
 !65 1.00  
 >65 1.98 (1.56-2.52) <0.0001 
Gender   
Female 1.00  
Male 1.01 (0.80-1.27) 0.925 
Stage   
Dukes A 1.00  
Dukes B 2.86 (1.36-6.01) 0.006 
Dukes C 7.84 (3.79-16.22) <0.0001 
Dukes D (0-1.25y) 51.173 (23.61-110.91) <0.0001 
Dukes D (1.25-1.5y) 31.398 (14.65-67.28) <0.0001 
Differentiation   
Grades 1-2 1.00  
Grades 3-4 (0-1.25y) 2.13 (1.52-2.98) <0.0001 
Grades 3-4(1.25-5.0y) 0.92 (0.62-1.37) 0.684 
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Table 11.D Cox multivariable analysis of relative risk of death from colorectal 
cancer within 5 years by combined PODXL expression by mAb HES9 and pAb 
HPA002110 
 
 HR (95% CI) p-value 
PODXL expression   
Low 1.00  
Moderate 1.63 (1.11-2.39) 0.012 
High 2.14 (1.12-4.07) 0.021 
Age   
 !65 1.00  
 >65 1.89 (1.50-2.40) <0.001 
Gender   
Female 1.00  
Male 1.06 (0.85-1.33) 0.601 
Stage   
Dukes A 1.00  
Dukes B 2.60 (1.29-5.27) 0.008 
Dukes C 7.01 (3.56-14.14) <0.0001 
Dukes D (0-1.25y) 46.46 (22.21-97.16) <0.0001 
Dukes D (1.25-1.5y) 25.88 (12.56-53.31) <0.0001 
Differentiation   
Grades 1-2 1.00  
Grades 3-4 (0-1.25y) 1.97 (1.40-2.76) <0.0001 
Grades 3-4 (1.25-5.0y) 0.79 (0.53-1.16) 0.231 















Table 11.E Cox multivariable analysis of relative risk of death from colorectal 
cancer within 5 years by CA19-9 expression 
 
 HR (95% CI) p-value 
CA19-9 expression   
Low 1.0  
High 1.80 (1.09-2.98) 0.023 
Age   
 !65 1.0  
 >65 1.65 (1.01-2.72) 0.047 
Gender   
Female 1.0  
Male 0.93 (0.57-1.53) 0.776 
Stage   
Dukes A 1.0  
Dukes B 7.75 (1.02-59.09) 0.048 
Dukes C 13.55 (1.81-101.31) 0.011 
Dukes D  70.25 (9.51-518.77) <0.0001 
Differentation   
Grades 1-2 1.0  
Grades 3-4  1.09 (0.58-2.05) 0.793 
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9. DISCUSSION 
9.1. Tumour markers 
9.1.1. Podocalyxin (PODXL) 
Studies I and II show PODXL to be an independent marker in CRC of poor 
prognosis.  The staining pattern of the two antibodies differed: by the mAb, 
patients with high cytoplasmic expression had a poor prognosis, whereas by the 
pAb, a similar phenomenon emerged for membranous PODXL expression. 
Correlations with clinicopathological parameters (except for tumour side) were 
similar, but interestingly, case-by-case expression of PODXL by mAb and pAb 
did not correlate. Compared to either antibody alone, combination of the results 
of both antibodies enlarged the group of patients with poor prognosis, and 
revealed a group with an even worse prognosis. 
 
 
As it is an anti-adhesive molecule, aberrant PODXL expression has been 
suggested to support the disruption of cell-to-cell and cell-to-extracellular 
matrix adhesion, thus promoting tumour dissemination (144). Its ectopic 
expression correlates with increased invasion in breast and prostate cancer 
(191). In CRC, high cytoplasmic expression by the mAb and membranous 
expression by the pAb correlated with poor differentiation, advanced disease 
stage, and poor survival, in accordance with the literature (146,149). 
Surprisingly, expression patterns varied, and case-by-case expression was not 
uniform between the two antibodies, even though they are known to recognise 
different epitopes within the extracellular portion of the PODXL molecule. As 
patients with concomitant high cytoplasmic PODXL expression by the mAb 
and membranous expression by the pAb had an even worse DSS than did those 
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with only membranous or only high cytoplasmic PODXL expression, it is 
possible that the two antibodies may describe a slightly different biological 
phase of PODXL in CRC. Possibly the polyclonal antibody recognises an active 
form of PODXL at the cell membrane, whereas the monoclonal antibody with 
its smaller target epitope is able to recognise overexpression of cytoplasmic 
PODXL, which either has a function in the cytoplasm, or is moving towards the 
cell membrane. Of every four patients with this concomitant positivity, nearly 
three had metastatic disease at diagnosis; this supports the role of PODXL 
overexpression in tumour-cell dissemination, later leading to metastases. 
 
Another possibility is that these antibodies recognise different variants of 
PODXL; of the four protein-coding PODXL splice variants, the epitope 
sequence of the pAb matches three of them 100% (PODXL 001, 005, and 201; 
The Human Protein Atlas). The fourth splice variant matches 87% (PODXL 
202). The epitope sequence of the mAb HES9 matches all splice variants 100%. 
 
The difference that emerged between the two antibodies in relation to 
clinicopathological parameters was that high cytoplasmic expression by the 
mAb was more common in the right hemicolon (RHC) than in the left (LHC), 
whilst no such difference appeared with the pAb. The division between tumours 
by tumour location suggested by Bufill (192) is not based solely on anatomical 
site. It is based also on developmental differences: the RHC is derived from 
midgut and perfused by the superior mesenteric artery with a multilayered 
capillary network, whereas the LHC is derived from hindgut and perfused by 
the inferior mesenteric artery with a single-layer capillary network. A recent 
study by Yamauchi (193) suggests no discrete transition point at the splenic 
flexure, but a gradual change in histological and molecular characteristics from 
!
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ascending colon to rectum. This difference between expression patterns of the 
two PODXL antibodies may be due to differing cytoplasmic activity of PODXL 
in left- compared to right-sided tumours, but this requires further validation. 
 
Both of the antibodies studied showed PODXL to be an independent marker in 
CRC of poor prognosis. No clear difference emerged between the two 
antibodies as prognostic markers, however, because their hazard ratios for 5-
year risk of death were almost identical. Their prognostic roles and associations 
with clinicopathological parameters (except for tumour location for the mAb) 
corresponded with the literature’s (146,149). 
 
The differing expression patterns of the two antibodies offer a possibility for 
their combined use. A simple combination of the expressions created two new 
groups; one with low cytoplasmic/non-membranous and other with high 
cytoplasmic or membranous expression or both. The combination defined a 
larger number of patients with poor prognosis than did either antibody alone.   
 
When combining the expression patterns into three new classes, we were able to 
identify a small group of patients with a grim prognosis. The size of this group 
was small, thus this phenomenon is of more biological interest than of clinical 
value. 
9.1.2. REG4 
Study IV showed that, in non-mucinous CRC, cytoplasmic REG4 expression 
associates with favourable clinicopathological parameters and that it is an 




In CRC, REG4 expression was higher in low-stage tumours and in those with  
mucinous histology. With mucinous tumours excluded, REG4 expression 
associated significantly with higher differentiation and low stage. REG4 
expression also associated with MUC1, MUC2, and MUC5AC, which supports 
the finding that REG4-positive tumours are more highly differentiated than are 
REG4-negative tumours. No association between REG4 and neuroendocrine 
differentitation emerged.  These results are in accordance with findings of Li et 
al (159) that REG4 IHC expression in CRC associates significantly with higher 
differentiation and with absence of venous invasion. Moreover, Li et al showed 
a trend-like association of REG4 expression with low T-stage, absence of 
lymph node metastasis, and local disease (Dukes A-B vs C-D). Similar results 
appear for gallbladder cancer, where positive REG4 IHC expression associates 
with higher tumour differentiation (194).  Numata et al (158) reported 
controversial results for CRC: that higher REG4 mRNA expression associates 
with higher differentiation, deeper invasion (T-stage), lymphatic invasion, liver 
metastasis, and more advanced stage.  They, however, measured mRNA levels 
by PCR, not by the actual protein expression. 
 
It is interesting that higher serum levels of REG4 occur in many carcinomas 
than in healthy controls: in pancreatic (154), gastric (153) and gallbladder 
cancers (194), suggesting a potential use for serum REG4 as a diagnostic 
biomarker. 
 
Study IV showed that REG4 IHC is a marker of favourable prognosis in non-
mucinous CRC, but controversial results have also emerged; elevated tissue 
levels of REG4 mRNA in CRC may be a marker of poor prognosis (158). In 
CRC, Li et al. (159) and Zheng et al. (160) saw no prognostic role for REG4 
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IHC expression, but they did not analyze mucinous and non-mucinous cancers 
separately. In addition, antibodies, staining procedures, and analysis of 
stainings may have differed from those in Study IV. 
 
REG4 expression is constitutively high in mucinous tumours such as 
pseudomyxoma peritonei and mucinous cystadenomas, and Study IV 
demonstrates that in CRC REG4, expression associates with markers of 
mucinous differentiation.   This may explain why immunohistochemistry found 
no clear variation in REG4 expression in the group of mucinous CRC tumours, 
and why REG4 IHC expression was a marker of favourable prognosis only in 
non-mucinous CRC. It thus seems plausible that in CRC patients with poor 
prognosis, REG4 mRNA levels may be elevated, but this is not translated to 
protein. Further studies are warranted to compare REG4 mRNA levels with 
REG4 IHC case by case. 
 
REG4 is expressed in inflammatory bowel diseases and also in the margins of 
peptic ulcers and is considered a marker of inflammation (104). In some whole-
tissue sections, tumour tissue stained negative for REG4, but the adjacent 
benign epithelium expressed REG4 strongly, apparently representing an 
inflammatory reaction against the tumour.  
 
In normal intestinal mucosa, high REG4 expression is apparent in the majority 
of entero-endocrine cells, with the co-expression of synaptophysin and 
chromogranin (104).  Considering this fact, it is interesting that no association 




Several reports suggest the oncogenic role of REG4 in the development of 
cancer in the gastrointestinal tract. The ultimate molecular mechanisms have, 
however, remained elusive. Bishnupari et al (195) reported that treatment of 
cultured colon adenocarcinoma cells with recombinant REG4 protein induced 
phosphorylation of the EGF (epidermal growth factor) receptor and Akt. They 
suggested that REG4 is a transactivator of the EGFR/Akt signaling pathway. A 
further elucidation of the role of exogenous REG4 as a regulator of cell growth 
potential is, however, awaiting identification of the putative REG4 receptor. No 
evidence shows that increased expression of REG4 by itself induces cancerous 
growth, however.  
 
Regulation of REG4 expression is still poorly understood. REG4 is up-
regulated in inflamed IBD mucosa and in IBD-like foci of gastritis-induced 
intestinal metaplasia in the stomach (104). This suggests that inflammatory 
cytokines may influence REG4 expression. Moreover, physiological REG4 
expression is evident in cells with neuroendocrine differentiation, where REG4 
co-expresses in neuroendocrine tumours with the neuronal transcription factor 
Hath-1 (atonal, Math-1) (151), one possible regulator of REG4.  
 
 
9.1.3. N-glycosylation in colorectal cancer 
Study III shows by MALDI-TOF MS analysis that the acidic and neutral N-
glycan profiles of rectal adenomas and carcinomas clearly differ, and that 
principal component analysis of specific N-glycans can separate adenomas from 
carcinomas. Several specific N-glycan structure types were identified whose 
amounts in carcinomas either increase or decrease during adenoma-carcinoma 
transition or cancer progression. Differences in the amount of N-glycan 
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structures also appeared: between local and locoregional disease and between 
local and advanced cancer.  
 
Sulphate esters are typical modifications of the digestive tract glycans (196) , 
and they were also apparent in previous glycosylation analyses of colorectal 
carcinoma and normal tissue samples (122). Sialylation, on the other hand, is 
more common in most tissues of the human body. Study III showed that N-
glycan profiles of adenomas were complex and rich in the terminal glycan 
modifications typical of colon glycosylation. These included acidic esters partly 
replacing sialylation and also complex fucosylation of N-glycans. In 
comparison, in the acidic N-glycan profiles of the carcinomas, a drastic loss of 
rectal epithelial glycosylation features was apparent, including the acid ester 
modifications. Thus, the carcinomas showed dedifferentiation from the normal 
tissue-specific glycosylation, which was especially prominent at advanced 
stages. However, alongside dedifferentiation many glycan structures were 
increased in carcinomas, thus serving as potential novel cancer biomarkers.  
 
Principal component analysis clearly showed the homogeneity of adenomas’ N-
glycan profiles and the difference between carcinomas’ N-glycan profiles and 
those of adenomas, and differences among themselves. Similar differences 
appear between serous ovarian cystadenomas and serous carcinomas (Carpen, 
O et al, oral communication).  
 
The serum N-glycomic profile differs in CRC patients from that in normal 
controls; adenoma patients’ N-glycan profiles also differ from those of CRC 
patients (123). Seeing directly the changes in the glycomic profiles of tumour 
cells, however, requires MS analysis of the tissue, since changes in serum 
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glycosylation have been associated with altered glycosylation of 
immunoglobulins and of acute phase proteins (197,198). 
 
Balog et al (122) reported an increase in pauci-mannocidic structures, sulphated 
N-glycans (acid esters), and sialyl Lewis-type epitopes in CRC samples 
compared to normal levels in control samples. Results in Study III were in 
accordance in regards to pauci-mannosidic structures and glycan signals 
indicating sialyl-Lewis type structures, but the amounts of sulphated N-glycans 
were lower in carcinomas than in adenomas. Balog et al. had studied tumours 
originating from all of the colorectum, whereas tumours in Study III were of 
rectal origin; they also studied the difference between carcinoma tissue and 
adjacent normal tissue, but did not study adenomas. At a general level, results 
in Study III corresponded with those of Balog et al., a sign of this method’s 
repeatability.  
 
MS allows the identification of a large number of glycan structures whose 
expression differs between carcinomas and adenomas; these included increased 
sialylated and pauci-mannose structures. Moreover, differences between local 
carcinomas and metastasized tumours were visible. These glycan structures are 
potential tumour markers that should be studied in large patient series. Study III 
analyzed two candidate glycan: sLea, better known as serum tumour marker 
CA19-9, and pauci-mannose. High tissue expression of sLea has been correlated 
with poor prognosis and unfavourable clinicopathological parameters in CRC 
(199-201). Results of Study III are in accordance with these findings. Elevated 
expression of pauci-mannose N-glycans correlated with non-mucinous 
histology, and in advanced CRC it associated with poor prognosis. Pauci-
mannosidic structures have also been associated with lysosomal glycoproteins, 
!
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but the mechanism of their accumulation in malignant tumours is currently 
unknown. In addition to strong intracellular staining with the pauci-mannose 
antibody, we detected membraneous accumulation of these structures in cancer 
cells, which suggests the potential utility of this glycan group as a source of 
novel cancer-associated antigens. 
 
Because blood-group antigens are built of glycan structures, only patients with 
blood group A Rh+ were included in Study III for MS, to eliminate possible 
blood group influence. However, no signals in relation to this blood-group were 
observable, so it is possible that in future studies the influence of blood groups 
can be disregarded.  
 
The majority of glycosylation differences appeared between adenomas and 
carcinomas, but differences appeared also between local and more advanced 
carcinomas, differences that may reflect tumour ability to invade and 
metastasize. Most colorectal carcinomas arise from adenomas by accumulating 
mutations in key tumour-suppressor genes and oncogenes in a slow process 
taking from years to even decades.  Major protein glycosylation is already 
undergoing a shift from strictly tissue-specific N-glycan structures in adenomas 
into dedifferentiated glycosylation in early-stage carcinomas. Further studies 
are essential to study the possible role of such changed glycosylation in 
carcinoma invasion and metastasis.  
 
Study III indicates that in MS glycosylation analysis, a distinction is apparent 
between benign and malignant tumours. Based on PCA results, it is clear that a 
complex MS profile can be transformed into a simple equation, predicting 
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malignancy. A prospective study with a larger sample cohort should analyze the 
MS method’s sensitivity and specificity. 
 
Since both MS and data analysis can be automated, MS alone could prove 
clinically useful. The current price-tag for analysis of a N-glycan profile of one 
tissue sample ranges around 1000 !, but with automation and a sufficient 
number of samples to be analyzed, the cost would fall to around 100 ! per 
sample, making it competitive with traditional diagnostic methods. 
Biotechnological companies proposed a comparable serum proteomics method 
for clinical use at a similar price over a decade ago, but its insufficient 
sensitivity and specificity have remained a problem.  
 
In addition to pure MS analysis as a diagnostic tool, transforming differences in 
N-glycosylation found by MS into immunohistochemical or serum biomarker 
assays would prove useful. These methods require specific antibodies, which 
can either be produced or be sought in peptide libraries.  
 
9.2. Strengths and limitations of study materials and methods 
The TMA technique used in all four studies allows analysis of large patient 
cohorts, but allows analysis of only a small proportion of the tumour, which, 
considering intra-tumoural heterogeneity, could cause misinterpretation. 
However, with adequate multiple sampling from histologically representative 
areas, TMA leads to results that are in accordance with those from whole-tissue 
sections (187,202,203).  
 
The large patient cohort comprising almost 850 CRC patients consecutively 
operated on in HUH between 1983 and 2001 is well characterised 
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clinicopathologically, and the survival data were comprehensively gathered. 
This patient cohort has a long follow-up, but using old patient data has its 
limitations. Instead of today’s widely used TNM UICC, the modified Dukes 
stage according to ACPS was used, because it was used at HUH during the 
years of these patients’ primary treatment. Survival rates have also improved 
over time, due to improvements in surgical techniques, pathological staging, 
preoperative imaging, and oncological treatments. The number of lymph nodes 
has increased, with now a minimum of 12 lymph nodes studied and examined, 
leading to stage migration from stage II to stage III (204-206). This has led to 
improved prognosis in stage II as a consequence, and has also improved 
prognosis in stage III (often called the Will-Rogers phenomenon). In addition to 
leading to more frequent adjuvant therapies, stage migration has an impact on 
overall prognosis in CRC. 
 
In Study III, the number of tumour samples was relatively low, since analysis of 
the full N-glycan profile of tumour samples was both time-consuming and 
laborious. Possible variance in glycosylation resulting from tumour location 
was eliminated by including only tumours of the rectum. As blood-group 
antigens are built of glycan structures, only patients with blood group A Rh+ 
were included, to eliminate any possible influence. Such strict inclusion criteria 
allowed the use of a reasonably small sample cohort to identify significant 
glycosylation changes apparently related to carcinoma progression. 
 
9.3. Concluding remarks  
As colorectal cancer and other cancers are a growing burden in modern health 
care, all advances in prevention, diagnostics, and treatments are valuable. Novel 
biomarkers are essential to detect cancer earlier and to identify patients for 
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targeted and individualized therapy. Before drawing conclusions regarding the 
effect of a specific biomarker on individualized treatment, the biomarker’s 
prognostic and predictive role must be thoroughly validated in sufficiently large 
prospective clinical trials (207).  
 
This study confirms PODXL to be a marker of poor prognosis in CRC by 
means of two antibodies, each of which recognized its own group of patients 
with a poor prognosis. Combination of the two PODXL antibodies defined a 
larger number of patients with poor prognosis and also a small group of patients 
with an even worse prognosis. A trial combining both of the PODXL antibodies 
with PODXL gene-mutation information would be interesting and would 
further clarify the biological function of PODXL. Study IV showed that REG4 
IHC expression to be a marker of favourable prognosis in non-mucinous 
colorectal cancer. Although these results are in disagreement with those 
obtained by evaluating mRNA levels; our discrepancies with others’ findings 
warrant further studies. 
 
Study III showed that rectal adenomas can be identified from carcinomas based 
on MS analysis of their N-glycan profile. Glycosylation differences existed also 
between local and more advanced carcinoma. In the future carcinoma-related 
glycan structures identified in this study can be tested as potential prognostic 
biomarkers by detection of these glycan structures in situ by 
immunohistochemistry. Changes in glycosylation profile can evolve into a 
simpler equation that predicts malignancy, requiring validation in larger series. 
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10. CONCLUSIONS 
 
• PODXL was associated with unfavourable clinicopathological 
parameters and was an independent marker of poor prognosis in 
colorectal cancer. 
• The two PODXL antibodies studied recognised different groups of 
patients, both with poor prognosis. Combined use of the antibodies 
revealed a group with even worse prognosis. 
• REG4 IHC expression was associated with favourable 
clinicopathological parameters and was an independent marker of better 
prognosis in non-mucinous CRC. 
• N-glycan profiles or rectal adenomas and carcinomas differed.   
• MS analysis of N-glycan profiles can identify specific glycan structures 
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